VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Other Operating Liabilities
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Other Operating Liabilities of -$28.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$51.50M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $23.10M, a 5.00% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $105.80M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $83.90M, a 37.43% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for fiscal 2025 was $148.50M, a 274.06% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for fiscal 2024 was $39.70M, a 81.00% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for fiscal 2023 was $208.90M, a 58.13% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other operating liabilities for fiscal 2022 was $498.90M, a 2869.64% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Other Operating Liabilities 12 month | Increase (Decrease) in Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$51.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$28.40M 10-Q · filed 2026-08-04 | $77.40M derived: sum of 3 quarters · filed 2026-08-04 | $161.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $23.10M 10-Q · filed 2026-05-05 | $128.90M derived: sum of 2 quarters · filed 2026-05-05 | $212.80M derived: sum of 3 quarters · filed 2026-05-05 | $149.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $105.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $189.70M derived: sum of 2 quarters · filed 2026-02-13 | $126.50M derived: sum of 3 quarters · filed 2026-08-04 | $148.50M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $83.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $20.70M derived: sum of 2 quarters · filed 2026-08-04 | $42.70M 10-Q · filed 2025-11-04 | $37.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$63.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$41.20M 10-Q · filed 2026-08-04 | -$46.60M derived: sum of 3 quarters · filed 2026-08-04 | $87.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $22.00M 10-Q · filed 2026-05-05 | $16.60M derived: sum of 2 quarters · filed 2026-05-05 | $150.70M derived: sum of 3 quarters · filed 2026-05-05 | -$105.90M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $128.70M derived: sum of 2 quarters · filed 2026-02-13 | -$127.90M derived: sum of 3 quarters · filed 2026-02-13 | $39.70M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $134.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$122.50M derived: sum of 2 quarters · filed 2025-11-04 | $45.10M 10-Q · filed 2025-11-04 | $100.60M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | -$256.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$89.00M 10-Q · filed 2025-08-05 | -$33.50M derived: sum of 3 quarters · filed 2026-02-13 | $2.10M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $167.60M 10-Q · filed 2025-05-06 | $223.10M derived: sum of 2 quarters · filed 2026-02-13 | $258.70M derived: sum of 3 quarters · filed 2026-02-13 | $287.10M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $55.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $91.10M derived: sum of 2 quarters · filed 2026-02-13 | $119.50M derived: sum of 3 quarters · filed 2026-02-13 | $208.90M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $35.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $64.00M derived: sum of 2 quarters · filed 2024-11-05 | $153.40M 10-Q · filed 2024-11-05 | $693.00M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $28.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $117.80M 10-Q · filed 2024-08-02 | $657.40M derived: sum of 3 quarters · filed 2025-02-13 | $648.40M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $89.40M 10-Q · filed 2024-05-07 | $629.00M derived: sum of 2 quarters · filed 2025-02-13 | $620.00M derived: sum of 3 quarters · filed 2025-02-13 | $572.60M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $539.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $530.60M derived: sum of 2 quarters · filed 2025-02-13 | $483.20M derived: sum of 3 quarters · filed 2025-02-13 | $498.90M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | -$9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$56.40M derived: sum of 2 quarters · filed 2023-11-07 | -$40.70M 10-Q · filed 2023-11-07 | $43.40M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | -$47.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$31.70M 10-Q · filed 2023-08-02 | $52.40M derived: sum of 3 quarters · filed 2024-02-15 | $31.10M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $15.70M 10-Q · filed 2023-05-02 | $99.80M derived: sum of 2 quarters · filed 2024-02-15 | $78.50M derived: sum of 3 quarters · filed 2024-02-15 | $24.20M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $84.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $62.80M derived: sum of 2 quarters · filed 2024-02-15 | $8.50M derived: sum of 3 quarters · filed 2024-02-15 | $16.80M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | -$21.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | -$75.60M derived: sum of 2 quarters · filed 2022-10-28 | -$67.30M 10-Q · filed 2022-10-28 | -$67.33M 10-Q · filed 2021-11-03 | $61.32M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | -$54.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$46.00M 10-Q · filed 2022-08-05 | -$45.97M 10-Q · filed 2021-07-30 | $82.62M derived: sum of 3 quarters · filed 2023-02-10 | $349.37M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $8.30M 10-Q · filed 2022-05-06 | $8.28M 10-Q · filed 2021-04-30 | $136.92M derived: sum of 2 quarters · filed 2023-02-10 | $403.67M derived: sum of 3 quarters · filed 2023-02-10 | $375.59M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $128.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $395.37M derived: sum of 2 quarters · filed 2023-02-10 | $367.29M derived: sum of 3 quarters · filed 2023-02-10 | $425.10M 10-K · filed 2023-02-10 | $425.09M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $266.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $238.67M derived: sum of 2 quarters · filed 2021-11-03 | $296.48M 10-Q · filed 2021-11-03 | $311.62M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | -$28.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $29.73M 10-Q · filed 2021-07-30 | $44.88M derived: sum of 3 quarters · filed 2022-02-09 | $34.13M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $57.81M 10-Q · filed 2021-04-30 | $72.95M derived: sum of 2 quarters · filed 2022-02-09 | $62.20M derived: sum of 3 quarters · filed 2022-02-09 | $71.27M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $4.40M derived: sum of 2 quarters · filed 2022-02-09 | $13.46M derived: sum of 3 quarters · filed 2022-02-09 | $38.00M 10-K · filed 2022-02-09 | $38.00M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | -$10.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$1.68M derived: sum of 2 quarters · filed 2020-10-30 | $22.86M 10-Q · filed 2020-10-30 | $13.01M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $33.60M 10-Q · filed 2020-07-31 | $23.75M derived: sum of 3 quarters · filed 2021-02-11 | $30.17M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $24.54M 10-Q · filed 2020-05-01 | $14.69M derived: sum of 2 quarters · filed 2021-02-11 | $21.11M derived: sum of 3 quarters · filed 2021-02-11 | |||||
| 2018-12-31 | -$9.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$3.43M derived: sum of 2 quarters · filed 2021-02-11 | $22.14M 10-K · filed 2021-02-11 | |||||
| 2018-09-30 | $6.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $32.00M 10-Q · filed 2019-10-31 | ||||||
| 2018-06-30 | $25.57M 10-Q · filed 2019-08-01 | |||||||
| 2017-12-31 | -$20.86M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |